e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Basic mechanisms in malignant pleural disease biology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Osteopontin of either host or tumor origin critically affects malignant pleural effusion formation
I. Psallidas, G. Stathopoulos, C. Moschos, A. Kollintza, K. Karabela, D. Simoes, S. Papiris, I. Kalomenidis (Haidari, Athens, Greece)
Source:
Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Session:
Basic mechanisms in malignant pleural disease biology
Session type:
Oral Presentation
Number:
3852
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Psallidas, G. Stathopoulos, C. Moschos, A. Kollintza, K. Karabela, D. Simoes, S. Papiris, I. Kalomenidis (Haidari, Athens, Greece). Osteopontin of either host or tumor origin critically affects malignant pleural effusion formation. Eur Respir J 2010; 36: Suppl. 54, 3852
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of solitary fibrous tumours of the pleura: a systematic review and meta-analysis
Utility of pleural fluid for predictive marker testing in malignant pleural effusion
Massive pleural effusion presented with a very rare multitude of complication
Related content which might interest you:
Osteopontin is important for malignant pleural effusion formation
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
Host-derived osteopontin is important for malignant pleural effusion formation
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Malignant pleural effusion cells show aberrant glucose metabolism gene expression
Source: Eur Respir J 2011; 37: 1453-1465
Year: 2011
The value of IL6 in differentiation between malignant and non malignant pleural effusion
Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience
Year: 2009
All-
trans
-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice
Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology
Year: 2010
Talc mediates angiostasis in malignant pleural effusions via endostatin induction
Source: Eur Respir J 2007; 29: 761-769
Year: 2007
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma
Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions
Year: 2012
C-reactive protein in differentiation between tuberculous and malignant pleural effusions
Source: Annual Congress 2011 - Clinical challenges in tuberculosis
Year: 2011
Non-classical monocytes potentiates the pathogenesis of malignant pleural effusion via the production of IL-1ß
Source: International Congress 2019 – Biology of lung cancer
Year: 2019
Diagnostic usefulness of C reactive protein levels in pleural effusions of malignant and non malignant origin
Source: Eur Respir J 2007; 30: Suppl. 51, 431s
Year: 2007
Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion?
Source: International Congress 2017 – Pleural and mediastinal malignancies
Year: 2017
Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer
Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding
Year: 2019
Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM)
Source: International Congress 2017 – Mesothelioma and malignant pleural disease
Year: 2017
Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE)
Source: Eur Respir J 2007; 30: Suppl. 51, 103s
Year: 2007
Mast cells recruitment to malignant pleural effusions
Source: Annual Congress 2010 - Current issues in malignant pleural diseases
Year: 2010
A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma
Source: Eur Respir J 2010; 36: 1099-1105
Year: 2010
Is it important to determine pleural fluid amylase in patients with malignant pleural effusions?
Source: Eur Respir J 2007; 30: Suppl. 51, 565s
Year: 2007
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM)
Source: Eur Respir J 2004; 24: Suppl. 48, 81s
Year: 2004
Diagnostic value of detection of promoter hypermethylation of tumor suppressor genes in pleural fluid for diagnosis of malignant pleural effusion
Source: Annual Congress 2010 - Lung cancer, idiopathic pulmonary fibrosis and sarcoidosis: the genetic approach
Year: 2010
Correlation between pleural fluid cytological yield and pleural tumour burden in malignant pleural effusions
Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement?
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept